Chen, H

Garcia Sanchez, JJ

James, G

Kalantar-Zadeh, K

Kumar, S

Sloand, JA

Wittbrodt, E

Sanchez, JJ Garcia

eScholarship - University of California

UC IrvineUC Irvine Previously Published WorksTitlePUK6 COST AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ANEMIA IN CKD USING LINKED US CLAIMS AND ELECTRONIC HEALTH RECORDSPermalinkhttps://escholarship.org/uc/item/9zs7h4t3AuthorsWittbrodt, EJames, GKumar, Set al.Publication Date2020-05-01DOI10.1016/j.jval.2020.04.1465Copyright InformationThis work is made available under the terms of a Creative Commons Attribution License, availalbe at https://creativecommons.org/licenses/by/4.0/ Peer reviewedeScholarship.org Powered by the California Digital LibraryUniversity of CaliforniaPUK6COST AND HEALTHCARE RESOURCE USE IN PATIENTSWITH ANEMIA IN CKD USING LINKED US CLAIMS ANDELECTRONIC HEALTH RECORDSWittbrodt E,1 James G,2 Kumar S,3 Garcia Sanchez JJ,2 Chen H,3Sloand JA,3 Kalantar-Zadeh K41AstraZeneca, Wilmington, DE, USA, 2AstraZeneca, Cambridge, MD, UK,3AstraZeneca, Gaithersburg, MD, USA, 4University of California - Irvine, Irvine,CA, USAObjectives: Anemia is a routinely occurring complication in patients with chronic kidney disease (CKD), but current data regarding its economic impact are lacking. This study described direct costs and healthcare resource utilization in non-dialysis CKD patients with and without baseline anemia in real-world practice. Methods: This retrospective analysis of the integrated Limited Claims and Electronic Health Record (IBM Health, Armonk, NY) spanned Jan 1, 2012 to Sep 30, 2018. Pa-tients were aged $18 y with $2 eGFR measures ,60 mL/min/1.73 m2 $90 days apart. Anemia was defined as any hemoglobin (Hb) ,10 g/dL observed 6 6 months of confirmatory eGFR (baseline period). Total and site-specific costs and selected healthcare resource utilization were analyzed and stratified by presence of baseline anemia, Hb range, CKD stage, sex, and insurance type. Results: Of 22,720 patients, 23% (n=5283) had baseline anemia, 77% (17,437) did not, and females accounted for 60% and 56%, mean ages (6 SD) were 70 (14) and 70 (12) y, and median follow-up times were 2.9 and 3.8 y, respectively. Baseline anemia prevalence by CKD stage was 18% (3a), 25% (3b), 41% (4), and 73% (5). Median per patient total costs were $49012 and $31667, total hospitalization costs were $33479 and $22695, and total ER costs were $2232 and $1891, respectively. Median annual number of transfusions doubled (2 vs 1) and annual transfusion cost was 50% greater in patients with vs without baseline anemia, respectively. Slightly increased costs were associated with male sex and were markedly increased by advancing CKD stage (.3a), baseline Hb ,10, and supplemental Medicare and non-capitated insurance coverage. Con-clusions: Anemia is associated with substantially added direct cost and healthcare resource utilization experienced by patients with non-dialysis CKD, in both early and advanced stages and with lower Hb. Effective management of anemia in CKD offers an opportunity to address this ongoing burden. S378 VALUE IN HEALTH - MAY 2020

English

PUK6 COST AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ANEMIA IN CKD USING LINKED US CLAIMS AND ELECTRONIC HEALTH RECORDS

COST AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ANEMIA IN CKD USING LINKED US CLAIMS AND ELECTRONIC HEALTH RECORDS

COST AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ANEMIA IN CKD USING LINKED US CLAIMS AND ELECTRONIC HEALTH RECORDS

Abstract

Similar works

Full text

Available Versions

eScholarship - University of California